The PSA50 rate for all AR LBD mutation patients is 41%; It is effective for both single and compound mutations of L702H, and has a higher response rate for patients with T878/H875 co mutations; The tumor suppression effect is more long-lasting, and some patients have observed confirmed tumor shrinkage. The gene discussed is AR; the disease is neoplasm.